Jocasta Neuroscience focuses on developing innovative therapies for neurological disorders through its proprietary platform that leverages advanced gene therapy techniques. The company is dedicated to addressing unmet medical needs in conditions such as Alzheimer's disease and other neurodegenerative disorders. Their approach involves utilizing engineered viral vectors to deliver therapeutic genes directly to the affected areas of the nervous system, aiming to restore normal function and improve patient outcomes.

In addition to gene therapy, Jocasta Neuroscience employs cutting-edge research in neurobiology to better understand the underlying mechanisms of neurological diseases. This includes the use of advanced imaging techniques and biomarker discovery to facilitate the development of targeted treatments. By integrating these technologies, Jocasta aims to create a robust pipeline of products that not only address symptoms but also target the root causes of neurological disorders, ultimately enhancing the quality of life for patients.

United States

Jocasta Neuroscience, Inc. is a pre-clinical stage biotech company focused on developing a proprietary formulation of a-Klotho protein (JN-0413) to manage cognitive decline associated with various forms of neurodegenerative-induced dementia. Jocasta's foundational data demonstrates the critical role of a-Klotho in health and disease. Results ranging from human genetics (effect of KL mutations in humans) to robust cognitive enhancement in healthy rats, rodent disease models and non-human primates strongly support the advancement of JN-0413 into clinical trials in patients with dementia and cognitive decline.

Jocasta Neuroscience

Company Details